PPCB (Propanc Biopharma) Growth Rank: 0 (As of Jul. 09, 2026)


PPCB Propanc Biopharma Inc PPCB
29 GF Score
Price $1.78
! 2 Warning Signs
View Full Analysis

What is Propanc Biopharma Growth Rank?

Propanc Biopharma has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Propanc Biopharma Growth Rank Related Terms

PPCB
29GF Score
Propanc Biopharma Inc PPCB
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Propanc Biopharma Business Description

Address 302, 6 Butler Street, Cambwerwell, VIC, AUS, 3124
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.
29GF Score

Get the complete analysis for PPCB

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.78
Price